Not a traditional drug phase: TMS during sequence-demanding task for Effects of Cerebellar Stimulation on Brain Activation
Although there is increasing recognition that the cerebellum is involved in cognition as well as motor function, the manner in which the cerebellum contributes to cognition is uncertain. One theory that might account for both motor and cognitive contributions of the cerebellum is that the cerebellum is involved in sequencing of relevant events or stimuli.
Official registry: https://clinicaltrials.gov/study/NCT06108336 · Johns Hopkins University · enrollment listed as 50
What this phase means
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are TMS during sequence-demanding task, No TMS during sequence-demanding task, or TMS during non-sequence-demanding task. The registry lists allocation as randomized. Although there is increasing recognition that the cerebellum is involved in cognition as well as motor function, the manner in which the cerebellum contributes to cognition is uncertain.
They plan to enroll about 50 people at Baltimore. Taking part typically means a procedure as part of the study plus check-ins.
Official title (unrewritten)
Investigation of Cerebellar Involvement in Cognitive Sequencing
Interventions: TMS during sequence-demanding task, No TMS during sequence-demanding task, TMS during non-sequence-demanding task, No TMS during non-sequence-demanding task
Primary outcome (registry wording): functional magnetic resonance imaging brain activation
Who it is for (from inclusion criteria)
- Ages 18 Years to 50 Years
- 2\) educational attainment of at least 8 years;
- 4\) fluent speaker of English by self-report;
Who the registry excludes
- 1\) illicit drug use within 30 days of MRI scanning;
- 2\) neurological or systemic disorder which can cause dementia or cognitive dysfunction;
- 3\) history of an Axis I psychiatric disorder including substance use disorder;
- 4\) history of definite stroke;
- 5\) focal lesion on MRI exam;
- 6\) uncorrected visual deficits by self-report
- 7\) contraindications for MRI scanning
Public study contact (from the registry)
John E Desmond, Ph.D.
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Johns Hopkins University School of Medicine — Baltimore, Maryland (recruiting)
FAQ about this NCT record
Is NCT06108336 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06108336?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06108336?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary